Memorial Sloan Kettering Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

2020

  1. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy

    EBioMedicine, Vol. 53

2019

  1. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6742-6755

  2. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5

2016

  1. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer

    Cell, Vol. 166, Núm. 4, pp. 963-976

2015

  1. Mouse Models of Pancreatic Ductal Adenocarcinoma

    Hematology/Oncology Clinics of North America, Vol. 29, Núm. 4, pp. 609-617

  2. Organoid models of human and mouse ductal pancreatic cancer

    Cell, Vol. 160, Núm. 1-2, pp. 324-338